KRAS and cancer: K-ras mutations have a high frequency in cancer tissues with FIGO I-II clinical stages, significantly but not in FIGO III-IV stages, hence most of the carcinomas with k-ras point mutations were in early clinical stages may indicate that k-ras mutations commonly occur as an early event in the development of carcinogenesis (2, 38).